Cone-Rod Dystrophy Clinical Trials

7 recruitingLast updated: May 21, 2026

There are 7 actively recruiting cone-rod dystrophy clinical trials across 2 countries. Studies span Phase 2, Phase 1. Top locations include Dallas, Texas, United States, Baltimore, Maryland, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Cone-Rod Dystrophy Trials at a Glance

7 actively recruiting trials for cone-rod dystrophy are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Dallas, Baltimore, and Ann Arbor. Lead sponsors running cone-rod dystrophy studies include Ascidian Therapeutics, Inc, BlueRock Therapeutics, and Food and Drug Administration (FDA).

Browse cone-rod dystrophy trials by phase

About Cone-Rod Dystrophy Clinical Trials

Looking for clinical trials for Cone-Rod Dystrophy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cone-Rod Dystrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cone-Rod Dystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

Age-Related Macular DegenerationRetinal DegenerationRetinitis Pigmentosa+7 more
Food and Drug Administration (FDA)100 enrolled2 locationsNCT05355415
Recruiting

Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

Retinitis pigmentosa (RP)Cone-Rod DystrophyUsher Syndrome
Okuvision GmbH30 enrolled1 locationNCT07548944
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Stargardt DiseaseStargardt Disease 1Cone-Rod Dystrophy+1 more
Ascidian Therapeutics, Inc50 enrolled8 locationsNCT06445322
Recruiting
Phase 1Phase 2

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Stargardt DiseaseStargardt Disease 1Cone-Rod Dystrophy+1 more
Ascidian Therapeutics, Inc15 enrolled10 locationsNCT06467344
Recruiting
Phase 2

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Hearing LossSmith-Lemli-Opitz SyndromeCone-Rod Dystrophy
University of Colorado, Denver100 enrolled1 locationNCT01773278